Abstract
The treatment of rheumatoid arthritis (RA) in the last decade has made enormous advances with the use of biological therapies. However, these therapies have serious limitations such as the expense, side-effects, and the requirement for repeated injections, each of which can potentially be obviated by gene therapy. A gene therapy approach for the treatment of RA has the potential to stably deliver a gene product or multiple products in a target-specific, disease-inducible manner. There are many studies investigating gene therapy in RA, the majority of which have been designed to test proofof- principle in an animal model. With an abundance of animal studies that have established much promise, the field is now at the early stage of moving towards human trials, where patient benefit needs to overshadow associated risks, especially since RA is publicly perceived as a non-life-threatening disease. Here, we provide an overview that focuses on advances in the application of gene therapy to RA over the last five years, including: novel targets and approaches; the viral and non-viral applications most likely to succeed in the clinic; advances in our understanding of the contralateral effect; the latest successes with anti-inflammatory cytokines; and a review of advancements towards clinical trials.
Keywords: Adeno-associated virus, Angiogenesis, Animal models, Apoptosis, Contralateral effect, Electrotransfer, Interleukin-10, Signaling
Current Gene Therapy
Title: Gene Therapy for Rheumatoid Arthritis: Recent Advances
Volume: 8 Issue: 1
Author(s): James M. Woods, Yasmin Sitabkhan and Alisa E. Koch
Affiliation:
Keywords: Adeno-associated virus, Angiogenesis, Animal models, Apoptosis, Contralateral effect, Electrotransfer, Interleukin-10, Signaling
Abstract: The treatment of rheumatoid arthritis (RA) in the last decade has made enormous advances with the use of biological therapies. However, these therapies have serious limitations such as the expense, side-effects, and the requirement for repeated injections, each of which can potentially be obviated by gene therapy. A gene therapy approach for the treatment of RA has the potential to stably deliver a gene product or multiple products in a target-specific, disease-inducible manner. There are many studies investigating gene therapy in RA, the majority of which have been designed to test proofof- principle in an animal model. With an abundance of animal studies that have established much promise, the field is now at the early stage of moving towards human trials, where patient benefit needs to overshadow associated risks, especially since RA is publicly perceived as a non-life-threatening disease. Here, we provide an overview that focuses on advances in the application of gene therapy to RA over the last five years, including: novel targets and approaches; the viral and non-viral applications most likely to succeed in the clinic; advances in our understanding of the contralateral effect; the latest successes with anti-inflammatory cytokines; and a review of advancements towards clinical trials.
Export Options
About this article
Cite this article as:
Woods M. James, Sitabkhan Yasmin and Koch E. Alisa, Gene Therapy for Rheumatoid Arthritis: Recent Advances, Current Gene Therapy 2008; 8 (1) . https://dx.doi.org/10.2174/156652308783688482
DOI https://dx.doi.org/10.2174/156652308783688482 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Gender Disparity in Pediatric Diseases
Current Molecular Medicine Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment
Current Vascular Pharmacology Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Editorial (Hot Topic: Novel Enzyme Targets of Folate Metabolism)
Current Enzyme Inhibition Preface
Current Pharmaceutical Design Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot topic: Bisphosphonates and Bone Diseases: Past, Present and Future (Guest Editor: Dominique HEYMANN)]
Current Pharmaceutical Design Role of Biomechanical Force in Stem Cell-Based Therapy for Cartilage Repair
Current Rheumatology Reviews COX-2: Friend or Foe?
Current Pharmaceutical Design The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inhibitory Effect of Selective Cyclooxygenase-2 Inhibitor Etoricoxib on Human Organic Anion Transporter 3 (hOAT3)
Drug Metabolism Letters An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Alkaloids and Flavonoids as α1-Adrenergic Receptor Antagonists
Current Medicinal Chemistry